Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28655791.
- Also identified by DOI 10.1158/0008-5472.CAN-16-3538.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nrf2, a master regulator of oxidative stress, is considered a prominent target for prevention of hepatocellular carcinoma (HCC), one of the leading causes of cancer-related deaths worldwide. Here we report that <i>Nrf2</i>-deficient mice resisted diethylnitrosamine (DEN)-induced hepatocarcinogenesis without affecting P450-mediated metabolic activation of DEN. Nrf2 expression, nuclear translocation, and transcriptional activity were enhanced in liver tumors. Overactivated Nrf2 was required for hepatoma growth in DEN-induced HCC. Following DEN treatment, <i>Nrf2</i> genetic disruption reduced expression of pentose phosphate pathway-related enzymes, the depletion of which has been associated with an amelioration of HCC incidence. Conversely, enhanced Nrf2 activity was attributable to alterations in the ability to bind its endogenous inhibitor Keap1. Our findings provide a mechanistic rationale for Nrf2 blockade to prevent and possibly treat liver cancer. <i>Cancer Res; 77(18); 4797-808. ©2017 AACR</i>.
Medical subject headings
- Diethylnitrosamine
- Liver Neoplasms, Experimental
- NF-E2 Transcription Factor, p45 Subunit